The effects of administration of the Lactobacillus gasseri strain CP2305 on quality of life, clinical symptoms and changes in gene expression in patients with irritable bowel syndrome

Journal of Applied Microbiology

Volumn 122, Issue 1, 2017, Pages 212-224

  Nobutani, K ^a   Sawada, D ^b   Fujiwara, S ^b   Kuwano, Y ^c   Nishida, K ^c   Nakayama, J ^d   Kutsumi, H ^a   Azuma, T ^a   Rokutan, K ^c  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Asahi Soft Drinks Co Ltd   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

abdominal dysfunction; intestinal microbiota; Lactobacillus gasseri CP2305; leucocyte gene expression; probiotics

Indexed keywords

ABDOMINAL DYSFUNCTION; GENES EXPRESSION; INTESTINAL MICROBIOTA; IRRITABLE BOWEL SYNDROMES; LACTOBACILLUS GASSERI; LACTOBACILLUS GASSERI CP2305; LEUCOCYTE GENE EXPRESSION; LEUCOCYTES; MICROBIOTAS; PROBIOTICS;

GENE EXPRESSION;

INITIATION FACTOR 2; LACTOBACILLUS GASSERI EXTRACT; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE; PLACEBO; UNCLASSIFIED DRUG; PROBIOTIC AGENT;

BACTERIUM; BLOOD; CELLS AND CELL COMPONENTS; DIGESTIVE SYSTEM DISORDER; DISEASE SEVERITY; EUKARYOTE; GENE EXPRESSION; MICROBIOLOGY; PROBIOTICS; QUALITY OF LIFE; SYMPTOM;

ADULT; ARTICLE; BACTERIAL STRAIN; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY ASSESSMENT; DOWN REGULATION; FECES MICROFLORA; FEMALE; GENE EXPRESSION PROFILING; HUMAN; INTESTINE FLORA; IRRITABLE COLON; LACTOBACILLUS GASSERI; LEUKOCYTE; MALE; QUALITY OF LIFE; SIGNAL TRANSDUCTION; TREATMENT DURATION; UPREGULATION; CLINICAL TRIAL; GENETICS; IRRITABLE BOWEL SYNDROME; METABOLISM; MIDDLE AGED; PHYSIOLOGY; TREATMENT OUTCOME;

EUKARYOTA; LACTOBACILLUS GASSERI;

ADULT; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; LACTOBACILLUS GASSERI; MALE; MIDDLE AGED; PROBIOTICS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 85006973640     PISSN: 13645072     EISSN: 13652672     Source Type: Journal    
DOI: 10.1111/jam.13329     Document Type: Article

References (47)

1. Bercik, P. (2011) The microbiota-gut-brain axis: learning from intestinal bacteria? Gut 60, 288–289.
2. Buysse, D.J., Reynolds, C.F. 3rd, Monk, T.H., Berman, S.R. and Kupfer, D.J. (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28, 193–213.
3. Camilleri, M. (2012) Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 367, 1626–1635.
4. Camilleri, M., Lasch, K. and Zhou, W. (2012) Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol 303, G775–G785.
5. Cani, P.D., Everard, A. and Duparc, T. (2013) Gut microbiota, enteroendocrine functions and metabolism. Curr Opin Pharmacol 13, 935–940.
6. Clarke, G., Cryan, J.F., Dinan, T.G. and Quigley, E.M. (2012) Review article: probiotics for the treatment of irritable bowel syndrome – focus on lactic acid bacteria. Aliment Pharmacol Ther 35, 403–413.
7. Collins, S.M. and Bercik, P. (2009) The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology 136, 2003–2014.
8. Collins, S.M., Surette, M. and Bercik, P. (2012) The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol 10, 735–742.
9. Cryan, J.F. and Dinan, T.G. (2012) Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 13, 701–712.
10. Drossman, D.A. (2006) Rome III: The Functional Gastrointestinal Disorders. McLean, VA: Degnon Associates.
11. Drossman, D.A., Camilleri, M., Mayer, E.A. and Whitehead, W.E. (2002) AGA technical review on irritable bowel syndrome. Gastroenterology 123, 2108–2131.
12. DuPont, H.L. (2014) Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets. Aliment Pharmacol Ther 39, 1033–1042.
13. Ford, A.C., Spiegel, B.M., Talley, N.J. and Moayyedi, P. (2009) Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol 7, 1279–1286.
14. Foster, J.A. and McVey Neufeld, K.A. (2013) Gut-brain axis: how the microbiome influences anxiety and depression. Trends Neurosci 36, 305–312.
15. Gralnek, I.M., Hays, R.D., Kilbourne, A., Naliboff, B. and Mayer, E.A. (2000) The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 119, 654–660.
16. Grenham, S., Clarke, G., Cryan, J.F. and Dinan, T.G. (2011) Brain-gut-microbe communication in health and disease. Front Physiol 2, 94.
17. Holcik, M. and Sonenberg, N. (2005) Translational control in stress and apoptosis. Nat Rev Mol Cell Biol 6, 318–327.
18. Hoveyda, N., Heneghan, C., Mahtani, K.R., Perera, R., Roberts, N. and Glasziou, P. (2009) A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 9, 1–11.
19. Hughes, P.A., Zola, H., Penttila, I.A., Blackshaw, L.A., Andrews, J.M. and Krumbiegel, D. (2013) Immune activation in irritable bowel syndrome: can neuroimmune interactions explain symptoms? Am J Gastroenterol 108, 1066–1074.
20. Kajander, K., Hatakka, K., Poussa, T., Färkkilä, M. and Korpela, R. (2005) A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 22, 387–394.
21. Kajander, K., Myllyluoma, E., Rajilić-Stojanović, M., Kyronpalo, S., Rasmussen, M., Jarvenpaa, S., Zoetendal, E.G., de Vos, W.M. et al. (2008) Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther 27, 48–57.
22. Kanazawa, M., Drossman, D.A., Shinozaki, M., Sagami, Y., Endo, Y., Palsson, O.S., Hongo, M., Whitehead, W.E. et al. (2007) Translation and validation of a Japanese version of the irritable bowel syndrome-quality of life measure (IBS-QOL-J). Biopsychosoc Med 1, 1–7.
23. Kassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J. et al. (2007) The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133, 24–33.
24. Kim, H.J., Vazquez Roque, M.I., Camilleri, M., Stephens, D., Burton, D.D., Baxter, K., Thomforde, G. and Zinsmeister, A.R. (2005) A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 17, 687–696.
25. Kuwano, Y., Kamio, Y., Kawai, T., Katsuura, S., Inada, N., Takaki, A. and Rokutan, K. (2011) Autism-associated gene expression in peripheral leucocytes commonly observed between subjects with autism and healthy women having autistic children. PLoS ONE 6, e24723.
26. Lee, B.J. and Bak, Y.T. (2011) Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil 17, 252–266.
27. Logan, A.C., Venket Rao, A. and Irani, D. (2003) Chronic fatigue syndrome: lactic acid bacteria may be of therapeutic value. Med Hypotheses 60, 915–923.
28. Lozupone, C.A., Stombaugh, J.I., Gordon, J.I., Jansson, J.K. and Knight, R. (2012) Diversity, stability and resilience of the human gut microbiota. Nature 489, 220–230.
29. Malinen, E., Rinttila, T., Kajander, K., Matto, J., Kassinen, A., Krogius, L., Saarela, M., Korpela, R. et al. (2005) Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 100, 373–382.
30. Matricon, J., Meleine, M., Gelot, A., Piche, T., Dapoigny, M., Muller, E. and Ardid, D. (2012) Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther 36, 1009–1031.
31. Mayer, E.A., Tillisch, K. and Gupta, A. (2015) Gut/brain axis and the microbiota. J Clin Invest 125, 926–938.
32. McFarland, L.V. and Dublin, S. (2008) Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 14, 2650–2661.
33. Moayyedi, P., Ford, A.C., Talley, N.J., Cremonini, F., Foxx-Orenstein, A.E., Brandt, L.J. and Quigley, E.M.M. (2010) The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 59, 325–332.
34. Nakayama, J. (2010) Pyrosequence-based 16S rRNA profiling of gastro-intestinal microbiota. Biosci Microflora 29, 83–96.
35. O'Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O'Sullivan, G.C., Kiely, B. et al. (2005) Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128, 541–551.
36. Pakos-Zebrucka, K., Koryga, I., Mnich, K., Ljujic, M., Samali, A. and Gorman, A.M. (2016) The integrated stress response. EMBO Rep 17,e201642195.
37. de Palma, G., Collins, S.M., Bercik, P. and Verdu, E.F. (2014) The microbiota-gut-brain axis in gastrointestinal disorders: stressed bugs, stressed brain or both? J Physiol 592, 2989–2997.
38. Pestova, T.V., Kolupaeva, V.G., Lomakin, I.B., Pilipenko, E.V., Shatsky, I.N., Agol, V.I. and Hellen, C.U. (2001) Molecular mechanisms of translation initiation in eukaryotes. Proc Natl Acad Sci USA 98, 7029–7036.
39. Rajilić-Stojanović, M., Biagi, E., Heilig, H.G., Kajander, K., Kekkonen, R.A., Tims, S. and de Vos, W.M. (2011) Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 141, 1792–1801.
40. Rhee, S.H., Pothoulakis, C. and Mayer, E.A. (2009) Principles and clinical implications of the brain-gut-enteric microbiota axis. Nature Rev Gastroenterol Hepatol 6, 306–314.
41. Rokutan, K., Morita, K., Masuda, K., Tominaga, K., Shikishima, M., Teshima-Kondo, S., Omori, T. and Sekiyama, A. (2005) Gene expression profiling in peripheral blood leukocytes as a new approach for assessment of human stress response. J Med Invest 52, 137–144.
42. Rousseaux, C., Thuru, X., Gelot, A., Barnich, N., Neut, C., Dubuquoy, L., Dubuquoy, C., Merour, E. et al. (2007) Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 13, 35–37.
43. Sawada, D., Sugawara, T., Ishida, Y., Aihara, K., Aoki, Y., Takehara, I., Takano, K. and Fujiwara, S. (2016) Effect of continuous ingestion of a beverage prepared with Lactobacillus gasseri CP2305 inactivated by heat treatment on the regulation of intestinal function. Food Res Int 79, 33–39.
44. Shinozaki, M., Kanazawa, M., Sagami, Y., Endo, Y., Hongo, M., Drossman, D.A., Whitehead, W.E. and Fukudo, S. (2006) Validation of the Japanese version of the Rome II modular questionnaire and irritable bowel syndrome severity index. J Gastroenterol 41, 491–494.
45. Surdea-Blaga, T., Baban, A. and Dumitrascu, D.L. (2012) Psychosocial determinants of irritable bowel syndrome. World J Gastroenterol 18, 616–626.
46. Tillisch, K. (2014) The effects of gut microbiota on CNS function in humans. Gut Microbes 5, 404–410.
47. Yatsunenko, T., Rey, F.E., Manary, M.J., Trehan, I., Dominguez-Bello, M.G., Contreras, M., Magris, M., Hidalgo, G. et al. (2012) Human gut microbiome viewed across age and geography. Nature 486, 222–227.